MEI Pharma ($MEIP) is a NASDAQ-listed $133M biotech based in San Diego that was spun out by prior owner Australian biotech Novogen ($NVGN), a firm now facing NASDAQ delisting for failing to meet requirements, in 2012. Though I can certainly understand the reluctance of rational biotech investors to avoid any firm even vaguely associated with […]